Reading the tape
NASDAQ: GILD
Gilead Sciences, Inc.
Healthcare · Drug Manufacturers - General
Market Cap
$165.68B
52w High
$157.29
52w Low
$95.30
P/E
19.48
Volume
5.96M
Outstanding Shares
1.24B
Price vs Fundamentals
Why The Stock Is Moving
Mixed / unclearLow confidence
Note: The most recent financial data is over 3 months old. Metrics shown may not reflect the latest reporting period.
1Y Price: 29.12%Revenue (TTM): 2.4%FCF (TTM): -8.25%P/FCF: 100th pct
What changed
The stock rose 29.12% over the last year. Revenue grew 2.4% over the trailing twelve months. Operating margin moved from 5.78% to 37.37%. Free cash flow declined 8.25% over the trailing twelve months.
What the market seems to be pricing
The stock has moved higher against modestly improving underlying metrics. The operating data does not yet tell a clear story — the move may reflect sentiment, sector rotation, or macro factors rather than company-specific earnings power.
What would invalidate this read
Operating margin currently stands at 37.37%. A decisive move in revenue — currently up 2.4% — would be the clearest signal to resolve the ambiguity.
Company profile
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally.
CEODaniel O'Day
SectorHealthcare
IndustryDrug Manufacturers - General
Employees17,600
IPO dateJan 22, 1992
Valuation
Forward P/E—
EV/EBITDA15.69
Enterprise value$169.72B
Stock splits
Jan 28, 2013↑ Forward
Every 1 shares became 2
Jun 25, 2007↑ Forward
Every 1 shares became 2
Sep 7, 2004↑ Forward
Every 1 shares became 2
Mar 8, 2002↑ Forward
Every 1 shares became 2
Feb 22, 2001↑ Forward
Every 1 shares became 2
Profitability & growth
Revenue growth4.7%
Gross margin80.8%▲10.77%vs FY2024
Operating margin37.37%▲594.37%vs FY2024
ROE37.62%▲1415.19%vs FY2024
Analyst consensus
RatingBuy
Target price$161.88▲21.28%
37
Buy
20
Hold
1
Sell
Analyst ratings tend to be lagging indicators. Use as one signal among many.
Earnings
Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.
Next report
May 7, 2026
Q2 FY26 · EPS est $1.89 · Revenue est $6.91B
View
Dividends
$3.19/shareQuarterlyDividend Achiever · 10yrSafeGILD pays a dividend with a 2.39% dividend yield, 10 consecutive years of growth, growing at 3.01% annually, covered 2.4× by free cash flow.
Dividend Yield
2.39%
Annual Div / Share
$3.19
5yr CAGR
+3.01%
Doubles every ~23.4yr
Payout Ratio
47.04%
Safe
Dividend Growth Rate
3yr CAGR
+2.76%
5yr CAGR
+3.01%
10yr CAGR
+6.37%
Dividend Safety
9/10Safe
Dividend History
Annualized dividend cycles per share
YearAnnual DivYoY
2025$3.19+2.9%
2024$3.10+2.6%
2023$3.02+2.7%
2022$2.94+2.8%
2021$2.86+4.0%
2020$2.75+7.0%
2019$2.57+9.8%
Income Projection
Invest
$
Growth rate:
Reinvest dividends
Today
$24/yr
$2/mo
In 5 yrs
$28/yr+16%
$2/mo
In 10 yrs
$32/yr+35%
$3/mo
| Today | In 5 yrs | In 10 yrs |
|---|---|---|
$24/yr $2/mo | $28/yr+16% $2/mo | $32/yr+35% $3/mo |
Yield-on-cost grows from 2.39% → 3.22% over 10yr
Analysis
Dividend Strengths
Dividend Achiever
GILD has raised its dividend for 10 consecutive years — qualifying as a Dividend Achiever, demonstrating long-term commitment to shareholder income.
Well-covered by free cash flow
The dividend is covered 2.4× by free cash flow, indicating the company generates sufficient cash to sustain and potentially grow the payout without straining its finances.
Risks to Watch
No strong risk signal stands out from the latest period pair.